SELENOK

Across TCGA pan-cancer cohorts, SELENOK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SELENOK data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SELENOK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOK expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where SELENOK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	0.067	1.000	.024	19	view →
PDAC	DFS	Median	All	0.704	0.887	.004	11	view →
UCEC	DFS	Median	III,IV	0.889	0.460	.044	4	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SELENOK–CCRCC (OS)

Open the CCRCC breakdown →